お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
デフォルト表紙
市場調査レポート
商品コード
1005139

潰瘍性大腸炎の世界市場:薬剤タイプ別、疾患別の予測(2026年まで)- COVID-19の累積的影響

Ulcerative Colitis Market Research Report by Drug Type, by Disease, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版日: | 発行: 360iResearch LLP | ページ情報: 英文 192 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.74円
潰瘍性大腸炎の世界市場:薬剤タイプ別、疾患別の予測(2026年まで)- COVID-19の累積的影響
出版日: 2021年06月01日
発行: 360iResearch LLP
ページ情報: 英文 192 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の潰瘍性大腸炎の市場規模は、2020年の57億4,045万米ドルから2025年末までに85億8,532万米ドルに拡大すると予想されています。

COVID-19は、ほぼすべての業界に影響を与えた未曾有の世界の公衆衛生上の緊急事態であるため、予測期間中に業界の成長に長期的な影響を与えると予測されています。当レポートでは、根底にあるCOVID-19の問題と今後の道筋を確実に扱うために、調査範囲を広げ消費者の行動と需要の変化、購入パターン、サプライチェーンの再ルーティング、現在の市場動向、および政府の重要な介入などを考慮しながら、COVID-19の影響について考察しています。

当レポートは、世界の潰瘍性大腸炎市場について調査しており、市場の機会や課題、成長および抑制要因、COVID-19の累積的影響、薬剤タイプ・疾患・地域別の市場分析、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 序文

  • 調査の目的
  • 市場セグメンテーションとカバレッジ
  • 調査期間
  • 通貨と価格
  • 言語
  • 制限事項
  • 利害関係者

第2章 調査手法

  • 調査プロセス
    • 定義:調査目的
    • 決定:調査設計
    • 準備:調査機器
    • 収集:データソース
    • 分析:データの解釈
    • 策定:データ検証
    • 公開:調査レポート
    • 繰り返し:レポートの更新
  • 調査の実行
    • 開始:調査プロセス
    • 計画:調査計画を作成する
    • 実行:調査を実施する
    • 検証:発見と分析
    • 出版物:調査報告
  • 調査の成果

第3章 エグゼクティブサマリー

  • 市場展望
  • 薬剤タイプ別市場の展望
  • 疾患別市場の展望
  • 地域別市場の展望
  • 競合他社の見通し

第4章 市場概要

  • COVID-19の累積的影響

第5章 市場の洞察

  • 市場力学
    • 成長要因
    • 抑制要因
    • 市場機会
    • 課題
  • ポーターのファイブフォース分析

第6章 薬剤タイプ別市場

  • 抗TNF生物製剤
  • 抗炎症薬
  • カルシニューリン阻害剤
  • 免疫抑制剤

第7章 疾患別市場

  • 劇症大腸炎
  • 左側大腸炎
  • 膵炎または一般的な大腸炎
  • 直腸S状結腸炎
  • 潰瘍性直腸炎

第8章 南北アメリカ市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • 韓国
  • タイ

第10章 欧州、中東・アフリカ市場

  • フランス
  • ドイツ
  • イタリア
  • オランダ
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • FPNVポジショニングマトリックス
    • 象限
    • 事業戦略
    • 製品の満足度
  • 市場ランキング分析
  • 市場シェア分析
  • 競合他社のSWOT分析
  • 競合シナリオ
    • 合併・買収
    • 契約、コラボレーション、およびパートナーシップ
    • 新製品の発売と強化
    • 投資と資金調達
    • 評価、認知、拡大

第12章 企業プロファイル

  • Abbott Laboratories
  • AbbVie Inc.
  • Ajinomoto Pharmaceuticals Co., Ltd.
  • AstraZeneca PLC
  • Avaxia Biologics Inc.
  • Avaxia Biologics Inc.
  • Bausch Health Companies Inc.
  • BioLineRx Ltd
  • Boehringer Ingelheim GmbH
  • Celgene Corporation
  • Circle33, LLC
  • Cosmo Pharmaceuticals NV
  • Eli Lilly and Company
  • Ferring B.V.
  • GlaxoSmithKline PLC
  • InDex Pharmaceuticals Holding AB
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceuticals
  • Teva Pharmaceuticals Ltd
  • UCB S.A.

第13章 付録

  • ディスカッションガイド
  • ライセンスと価格
図表

LIST OF FIGURES

  • FIGURE 1. GLOBAL ULCERATIVE COLITIS MARKET SIZE, 2020 VS 2026 (USD MILLION)
  • FIGURE 2. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2020 (USD MILLION)
  • FIGURE 3. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2020 (USD MILLION)
  • FIGURE 4. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
  • FIGURE 5. GLOBAL ULCERATIVE COLITIS MARKET: MARKET DYNAMICS
  • FIGURE 6. GLOBAL ULCERATIVE COLITIS MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 7. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2020 VS 2026 (%)
  • FIGURE 8. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2020 VS 2026 (USD MILLION)
  • FIGURE 9. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2026
  • FIGURE 10. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ANTI-TNF BIOLOGICS, 2018-2026 (USD MILLION)
  • FIGURE 11. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ANTI-TNF BIOLOGICS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 12. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ANTI-INFLAMMATORY DRUGS, 2018-2026 (USD MILLION)
  • FIGURE 13. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ANTI-INFLAMMATORY DRUGS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 14. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY CALCINEURIN INHIBITORS, 2018-2026 (USD MILLION)
  • FIGURE 15. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 16. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOSUPPRESSANT, 2018-2026 (USD MILLION)
  • FIGURE 17. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOSUPPRESSANT, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 18. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2020 VS 2026 (%)
  • FIGURE 19. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2020 VS 2026 (USD MILLION)
  • FIGURE 20. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2026
  • FIGURE 21. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY FULMINANT COLITIS, 2018-2026 (USD MILLION)
  • FIGURE 22. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY FULMINANT COLITIS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 23. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY LEFT-SIDED COLITIS, 2018-2026 (USD MILLION)
  • FIGURE 24. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY LEFT-SIDED COLITIS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 25. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PANCOLITIS OR UNIVERSAL COLITIS, 2018-2026 (USD MILLION)
  • FIGURE 26. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PANCOLITIS OR UNIVERSAL COLITIS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 27. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PROCTOSIGMOIDITIS, 2018-2026 (USD MILLION)
  • FIGURE 28. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PROCTOSIGMOIDITIS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 29. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ULCERATIVE PROCTITIS, 2018-2026 (USD MILLION)
  • FIGURE 30. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ULCERATIVE PROCTITIS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 31. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 32. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 33. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 34. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 35. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 36. CANADA ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 37. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 38. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 39. CALIFORNIA ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 40. FLORIDA ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 41. ILLINOIS ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 42. NEW YORK ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 43. OHIO ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 44. PENNSYLVANIA ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 45. TEXAS ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 46. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 47. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 48. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 49. CHINA ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 50. INDIA ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 51. INDONESIA ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 52. JAPAN ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 53. MALAYSIA ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 54. PHILIPPINES ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 55. SOUTH KOREA ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 56. THAILAND ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 57. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 58. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 59. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 60. FRANCE ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 61. GERMANY ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 62. ITALY ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 63. NETHERLANDS ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 64. QATAR ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 65. RUSSIA ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 66. SAUDI ARABIA ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 67. SOUTH AFRICA ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 68. SPAIN ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 69. UNITED ARAB EMIRATES ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 70. UNITED KINGDOM ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 71. GLOBAL ULCERATIVE COLITIS MARKET: FPNV POSITIONING MATRIX
  • FIGURE 72. GLOBAL ULCERATIVE COLITIS MARKET: SHARE, BY QUADRANT, 2020
  • FIGURE 73. GLOBAL ULCERATIVE COLITIS MARKET: SHARE, BY COMPANY, 2020
  • FIGURE 74. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ULCERATIVE COLITIS MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL ULCERATIVE COLITIS MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 4. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ANTI-TNF BIOLOGICS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 5. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ANTI-INFLAMMATORY DRUGS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 6. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 7. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOSUPPRESSANT, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 8. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 9. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY FULMINANT COLITIS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 10. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY LEFT-SIDED COLITIS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 11. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PANCOLITIS OR UNIVERSAL COLITIS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 12. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PROCTOSIGMOIDITIS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 13. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ULCERATIVE PROCTITIS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 14. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 15. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 16. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 17. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 18. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 19. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 20. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 21. CANADA ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 22. CANADA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 23. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 24. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 25. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 26. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 27. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 28. CALIFORNIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 29. CALIFORNIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 30. FLORIDA ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 31. FLORIDA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 32. ILLINOIS ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 33. ILLINOIS ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 34. NEW YORK ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 35. NEW YORK ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 36. OHIO ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 37. OHIO ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 38. PENNSYLVANIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 39. PENNSYLVANIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 40. TEXAS ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 41. TEXAS ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 42. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 43. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 44. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 45. CHINA ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 46. CHINA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 47. INDIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 48. INDIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 49. INDONESIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 50. INDONESIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 51. JAPAN ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 52. JAPAN ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 53. MALAYSIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 54. MALAYSIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 55. PHILIPPINES ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 56. PHILIPPINES ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 57. SOUTH KOREA ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 58. SOUTH KOREA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 59. THAILAND ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 60. THAILAND ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 64. FRANCE ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 65. FRANCE ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 66. GERMANY ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 67. GERMANY ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 68. ITALY ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 69. ITALY ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 70. NETHERLANDS ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 71. NETHERLANDS ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 72. QATAR ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 73. QATAR ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 74. RUSSIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 75. RUSSIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 76. SAUDI ARABIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 77. SAUDI ARABIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 78. SOUTH AFRICA ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 79. SOUTH AFRICA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 80. SPAIN ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 81. SPAIN ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 82. UNITED ARAB EMIRATES ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 83. UNITED ARAB EMIRATES ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 84. UNITED KINGDOM ULCERATIVE COLITIS MARKET SIZE, BY DRUG TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 85. UNITED KINGDOM ULCERATIVE COLITIS MARKET SIZE, BY DISEASE , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 86. GLOBAL ULCERATIVE COLITIS MARKET: SCORES
  • TABLE 87. GLOBAL ULCERATIVE COLITIS MARKET: BUSINESS STRATEGY
  • TABLE 88. GLOBAL ULCERATIVE COLITIS MARKET: PRODUCT SATISFACTION
  • TABLE 89. GLOBAL ULCERATIVE COLITIS MARKET: RANKING
  • TABLE 90. GLOBAL ULCERATIVE COLITIS MARKET: SHARE, BY QUADRANT, 2020
  • TABLE 91. GLOBAL ULCERATIVE COLITIS MARKET: SHARE, BY COMPANY, 2020
  • TABLE 92. GLOBAL ULCERATIVE COLITIS MARKET: MERGER & ACQUISITION
  • TABLE 93. GLOBAL ULCERATIVE COLITIS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 94. GLOBAL ULCERATIVE COLITIS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 95. GLOBAL ULCERATIVE COLITIS MARKET: INVESTMENT & FUNDING
  • TABLE 96. GLOBAL ULCERATIVE COLITIS MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 97. GLOBAL ULCERATIVE COLITIS MARKET: LICENSE & PRICING
  • TABLE 98. GLOBAL ULCERATIVE COLITIS MARKET: CONTACT DETAILS
目次
Product Code: MRR-0335FFDBEF3A

The Global Ulcerative Colitis Market size was estimated at USD 5,740.45 Million in 2020 and expected to reach USD 6,250.39 Million in 2021, at a Compound Annual Growth Rate (CAGR) 9.22% to reach USD 9,745.37 Million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Ulcerative Colitis to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Drug Type, the Ulcerative Colitis Market was studied across Anti-TNF Biologics, Anti-inflammatory Drugs, Calcineurin Inhibitors, and Immunosuppressant.

Based on Disease , the Ulcerative Colitis Market was studied across Fulminant Colitis, Left-sided Colitis, Pancolitis or Universal Colitis, Proctosigmoiditis, and Ulcerative Proctitis.

Based on Geography, the Ulcerative Colitis Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Ulcerative Colitis Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Ulcerative Colitis Market, including Abbott Laboratories, AbbVie Inc., Ajinomoto Pharmaceuticals Co., Ltd., AstraZeneca PLC, Avaxia Biologics Inc., Avaxia Biologics Inc., Bausch Health Companies Inc., BioLineRx Ltd, Boehringer Ingelheim GmbH, Celgene Corporation, Circle33, LLC, Cosmo Pharmaceuticals NV, Eli Lilly and Company, Ferring B.V., GlaxoSmithKline PLC, InDex Pharmaceuticals Holding AB, Johnson & Johnson Services, Inc., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Novartis International AG, Pfizer Inc., Sanofi SA, Takeda Pharmaceuticals, Teva Pharmaceuticals Ltd, and UCB S.A..

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Ulcerative Colitis Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Ulcerative Colitis Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Ulcerative Colitis Market?
  • 4. What is the competitive strategic window for opportunities in the Global Ulcerative Colitis Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Ulcerative Colitis Market?
  • 6. What is the market share of the leading vendors in the Global Ulcerative Colitis Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Ulcerative Colitis Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Drug Type Outlook
  • 3.4. Disease Outlook
  • 3.5. Geography Outlook
  • 3.6. Competitor Outlook

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of ulcerative colitis globally
      • 5.1.1.2. Robust availability of healthcare facilities and evolving drug development sector
      • 5.1.1.3. Availability of patient assistance programs and reimbursement policies
    • 5.1.2. Restraints
      • 5.1.2.1. Rise in patent expiry of drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development in the production of novel drugs
      • 5.1.3.2. Increasing public and private organization involvement in research of biologics
    • 5.1.4. Challenges
      • 5.1.4.1. Strict government mandates in approval of biosimilars
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Porters Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry

6. Ulcerative Colitis Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Anti-TNF Biologics
  • 6.3. Anti-inflammatory Drugs
  • 6.4. Calcineurin Inhibitors
  • 6.5. Immunosuppressant

7. Ulcerative Colitis Market, by Disease

  • 7.1. Introduction
  • 7.2. Fulminant Colitis
  • 7.3. Left-sided Colitis
  • 7.4. Pancolitis or Universal Colitis
  • 7.5. Proctosigmoiditis
  • 7.6. Ulcerative Proctitis

8. Americas Ulcerative Colitis Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States
    • 8.6.1. California
    • 8.6.2. Florida
    • 8.6.3. Illinois
    • 8.6.4. New York
    • 8.6.5. Ohio
    • 8.6.6. Pennsylvania
    • 8.6.7. Texas

9. Asia-Pacific Ulcerative Colitis Market

  • 9.1. Introduction
  • 9.2. China
  • 9.3. India
  • 9.4. Indonesia
  • 9.5. Japan
  • 9.6. Malaysia
  • 9.7. Philippines
  • 9.8. South Korea
  • 9.9. Thailand

10. Europe, Middle East & Africa Ulcerative Colitis Market

  • 10.1. Introduction
  • 10.2. France
  • 10.3. Germany
  • 10.4. Italy
  • 10.5. Netherlands
  • 10.6. Qatar
  • 10.7. Russia
  • 10.8. Saudi Arabia
  • 10.9. South Africa
  • 10.10. Spain
  • 10.11. United Arab Emirates
  • 10.12. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
    • 11.1.1. Quadrants
    • 11.1.2. Business Strategy
    • 11.1.3. Product Satisfaction
  • 11.2. Market Ranking Analysis
  • 11.3. Market Share Analysis, By Quadrant
  • 11.4. Market Share Analysis, By Company
  • 11.5. Competitive Scenario
    • 11.5.1. Merger & Acquisition
    • 11.5.2. Agreement, Collaboration, & Partnership
    • 11.5.3. New Product Launch & Enhancement
    • 11.5.4. Investment & Funding
    • 11.5.5. Award, Recognition, & Expansion

12. Company Usability Profiles

  • 12.1. Abbott Laboratories
  • 12.2. AbbVie Inc.
  • 12.3. Ajinomoto Pharmaceuticals Co., Ltd.
  • 12.4. AstraZeneca PLC
  • 12.5. Avaxia Biologics Inc.
  • 12.6. Avaxia Biologics Inc.
  • 12.7. Bausch Health Companies Inc.
  • 12.8. BioLineRx Ltd
  • 12.9. Boehringer Ingelheim GmbH
  • 12.10. Celgene Corporation
  • 12.11. Circle33, LLC
  • 12.12. Cosmo Pharmaceuticals NV
  • 12.13. Eli Lilly and Company
  • 12.14. Ferring B.V.
  • 12.15. GlaxoSmithKline PLC
  • 12.16. InDex Pharmaceuticals Holding AB
  • 12.17. Johnson & Johnson Services, Inc.
  • 12.18. Merck & Co., Inc.
  • 12.19. Mitsubishi Tanabe Pharma Corporation
  • 12.20. Novartis International AG
  • 12.21. Pfizer Inc.
  • 12.22. Sanofi SA
  • 12.23. Takeda Pharmaceuticals
  • 12.24. Teva Pharmaceuticals Ltd
  • 12.25. UCB S.A.

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing
  • 13.3. Contact Details
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.